Reported Earlier, Rhythm Pharmaceuticals Secures FDA Approval Of IMCIVREE For Rare Acquired Hypothalamic Obesity, Marking First-Ever Approved Treatment For The Disease
First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction
Indicated to reduce excess body weight and maintain reduction long-term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity
Approval based on -18.4% placebo-adjusted BMI reduction achieved by setmelanotide in global Phase 3 TRANSCEND trial [N=142]
Login to comment